MRI-guided Transurethral Ultrasound Ablation (TULSA) for Prostate Cancer

In this 19-minute presentation, Laurence Klotz, MD, Professor of Surgery at the University of Toronto and the Sunnybrook Chair of Prostate Cancer Research, discusses the technology, procedure, outcomes, and regulatory environment surrounding MRI-guided transurethral ultrasound ablation (TULSA) treatment for patients with prostate cancer. He cites data from a clinical trial that demonstrates 96 percent of patients had a PSA reduction ≥75 percent at 12 months and at the 12-month MRI the median prostate volume had decreased from 41 to 4 cc (a decrease of 90 percent). Further, the treatment preserved continence and erectile function.

For more presentations from the Southwest Prostate Cancer Symposium, visit our webpage: https://grandroundsinurology.com/spcs/